Login to Your Account

Financings Roundup

Investors Pony Up $27M for Acetylon's HDAC6 Inhibitors

By Trista Morrison

Wednesday, June 29, 2011
With early stage venture funding hard to come by, Acetylon Pharmaceuticals Inc. has found an alternative way to fund its development of isoform-selective histone deacetylase (HDAC) inhibitors. The Boston-based biopharma has raised $27 million in Series B financing from a large contingent of private individuals.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription